MetaCap

Beam Therapeutics (BEAM) vs Recursion Pharmaceuticals (RXRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Beam Therapeutics (BEAM) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, losing 5.9% versus a loss of 41.2%. Over five years, BEAM leads with a -73.4% price change compared with -87.0% for RXRX. Beam Therapeutics is the larger company by market cap ($2.16 billion vs $1.53 billion), about 1.4 times the size.

Beam Therapeutics converts more of its revenue into profit, with a net margin of -57.2% versus -863.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BEAM-5.90%RXRX-41.25%
+76%+15%-47%
Nov 21, 20251 yearNov 20, 2026
BEAM-76.70%RXRX-87.63%
+4%-44%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BEAM versus RXRX key metrics
MetricBEAMRXRX
Share price$20.90$2.45
Market cap$2.16B$1.53B
1-day change-0.19%-9.93%
YTD return-24.60%-40.10%
1-year return-5.90%-41.25%
5-year return-73.44%-87.04%
EPS (TTM)$-0.87$-0.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$139.74M$74.68M
Revenue growth (YoY)+120.01%+26.92%
Net income (latest FY)$-79.99M$-644.76M
Gross margin—4.99%
Operating margin-274.57%-867.87%
Net margin-57.24%-863.35%
52-week high$38.26$5.24
52-week low$20.44$2.44
Distance from 52-week high-45.37%-53.24%
Analyst consensusstrong_buybuy
Avg. price target upside+138.52%+176.33%
Average volume2.04M24.47M
Shares outstanding103.50M622.76M
Employees557600
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BEAM has outperformed RXRX by 35.3 percentage points over the past year.
  • Beam Therapeutics is more profitable, keeping -57.2 cents of every revenue dollar as net income versus -863.4 cents for Recursion Pharmaceuticals.
  • Beam Therapeutics grew revenue faster in its latest fiscal year (+120.01% vs +26.92%).

About Beam Therapeutics

BEAM stock →

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 557 employees

About Recursion Pharmaceuticals

RXRX stock →

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees

BEAM vs RXRX FAQ

Which is bigger, Beam Therapeutics or Recursion Pharmaceuticals?

Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.16B compared with $1.53B for Recursion Pharmaceuticals (RXRX).

Which stock has performed better over the past year, BEAM or RXRX?

BEAM returned -5.90% over the past 12 months, compared with -41.25% for RXRX (price return, excluding dividends). Past performance does not predict future results.

Are Beam Therapeutics and Recursion Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons